News Releases Joni Henderson 3/29/23 Joni Henderson 3/29/23 C₂N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research Read More Joni Henderson 2/16/23 Joni Henderson 2/16/23 C₂N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight Read More Guest User 12/8/22 Guest User 12/8/22 C₂N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood-Based Biomarkersin the Diagnosis of Alzheimer’s Disease Read More Guest User 11/29/22 Guest User 11/29/22 C₂N Diagnostics Introduces the PrecivityAD2™ Blood Test Read More Guest User 11/17/22 Guest User 11/17/22 International Researchers Poised to Learn New Insights About C₂N Diagnostics’ Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference Read More Guest User 10/21/22 Guest User 10/21/22 C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments Read More Guest User 9/21/22 Guest User 9/21/22 C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health Read More Guest User 9/14/22 Guest User 9/14/22 Independent Research Finds Underlying Method for C₂N’s p-Tau217 RatioBlood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses Read More Guest User 8/30/22 Guest User 8/30/22 C₂N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia Read More Guest User 8/23/22 Guest User 8/23/22 C₂N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings Read More Guest User 7/31/22 Guest User 7/31/22 C₂N Data Release for New Blood Test Combining p-tau217 Ratio with Amyloid beta 42/40 Read More Guest User 5/18/22 Guest User 5/18/22 C₂N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field Read More Tim West 4/21/22 Tim West 4/21/22 JAMA Network Open Publishes Analysis of Results of Two Independent Studies Demonstrating the High Diagnostic Performance of the PrecivityAD™ Blood Test for Alzheimer’s Disease Read More Guest User 2/22/22 Guest User 2/22/22 C₂N Achieves ISO 13485:2016 Certification Latest Development for Leader in Brain Health Sector Read More Guest User 1/3/22 Guest User 1/3/22 C₂N Begins New Year with CAP Accreditation Award, the Highest Standard in Laboratory Practices Read More Tim West 11/12/21 Tim West 11/12/21 Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis Read More Tim West 9/21/21 Tim West 9/21/21 C₂N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology Read More Joni Henderson 7/29/21 Joni Henderson 7/29/21 Two Research Studies Bolster Method That C₂N’s PrecivityAD™ Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses Read More Joni Henderson 6/8/21 Joni Henderson 6/8/21 C₂N Diagnostics Statement on FDA Accelerated Approval of Aducanumab for Alzheimer’s Treatment Read More Lee Q 5/27/21 Lee Q 5/27/21 Peer-Reviewed Journal Publishes Analytical Validation Results for the PrecivityAD™ Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease Read More Newer Posts Older Posts
Joni Henderson 3/29/23 Joni Henderson 3/29/23 C₂N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research Read More
Joni Henderson 2/16/23 Joni Henderson 2/16/23 C₂N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight Read More
Guest User 12/8/22 Guest User 12/8/22 C₂N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood-Based Biomarkersin the Diagnosis of Alzheimer’s Disease Read More
Guest User 11/29/22 Guest User 11/29/22 C₂N Diagnostics Introduces the PrecivityAD2™ Blood Test Read More
Guest User 11/17/22 Guest User 11/17/22 International Researchers Poised to Learn New Insights About C₂N Diagnostics’ Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference Read More
Guest User 10/21/22 Guest User 10/21/22 C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments Read More
Guest User 9/21/22 Guest User 9/21/22 C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health Read More
Guest User 9/14/22 Guest User 9/14/22 Independent Research Finds Underlying Method for C₂N’s p-Tau217 RatioBlood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses Read More
Guest User 8/30/22 Guest User 8/30/22 C₂N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia Read More
Guest User 8/23/22 Guest User 8/23/22 C₂N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings Read More
Guest User 7/31/22 Guest User 7/31/22 C₂N Data Release for New Blood Test Combining p-tau217 Ratio with Amyloid beta 42/40 Read More
Guest User 5/18/22 Guest User 5/18/22 C₂N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field Read More
Tim West 4/21/22 Tim West 4/21/22 JAMA Network Open Publishes Analysis of Results of Two Independent Studies Demonstrating the High Diagnostic Performance of the PrecivityAD™ Blood Test for Alzheimer’s Disease Read More
Guest User 2/22/22 Guest User 2/22/22 C₂N Achieves ISO 13485:2016 Certification Latest Development for Leader in Brain Health Sector Read More
Guest User 1/3/22 Guest User 1/3/22 C₂N Begins New Year with CAP Accreditation Award, the Highest Standard in Laboratory Practices Read More
Tim West 11/12/21 Tim West 11/12/21 Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis Read More
Tim West 9/21/21 Tim West 9/21/21 C₂N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology Read More
Joni Henderson 7/29/21 Joni Henderson 7/29/21 Two Research Studies Bolster Method That C₂N’s PrecivityAD™ Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses Read More
Joni Henderson 6/8/21 Joni Henderson 6/8/21 C₂N Diagnostics Statement on FDA Accelerated Approval of Aducanumab for Alzheimer’s Treatment Read More
Lee Q 5/27/21 Lee Q 5/27/21 Peer-Reviewed Journal Publishes Analytical Validation Results for the PrecivityAD™ Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease Read More
